BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 29119148)

  • 21. A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.
    Kodityal S; Elvin JA; Squillace R; Agarwal N; Miller VA; Ali SM; Klempner SJ; Ou SH
    Lung Cancer; 2016 Feb; 92():19-21. PubMed ID: 26775591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An evaluation of brigatinib as a promising treatment option for non-small cell lung cancer.
    Hamilton G; Hochmair MJ
    Expert Opin Pharmacother; 2019 Sep; 20(13):1551-1561. PubMed ID: 31328968
    [No Abstract]   [Full Text] [Related]  

  • 23. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
    Sgambato A; Casaluce F; Maione P; Gridelli C
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.
    Takahashi K; Seto Y; Okada K; Uematsu S; Uchibori K; Tsukahara M; Oh-Hara T; Fujita N; Yanagitani N; Nishio M; Okubo K; Katayama R
    Thorac Cancer; 2020 Mar; 11(3):581-587. PubMed ID: 31943796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial.
    Christopoulos P; Bozorgmehr F; Brückner L; Chung I; Krisam J; Schneider MA; Stenzinger A; Eickhoff R; Mueller DW; Thomas M
    BMC Cancer; 2021 Jun; 21(1):743. PubMed ID: 34182952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
    Camidge DR; Kim HR; Ahn MJ; Yang JC; Han JY; Lee JS; Hochmair MJ; Li JY; Chang GC; Lee KH; Gridelli C; Delmonte A; Garcia Campelo R; Kim DW; Bearz A; Griesinger F; Morabito A; Felip E; Califano R; Ghosh S; Spira A; Gettinger SN; Tiseo M; Gupta N; Haney J; Kerstein D; Popat S
    N Engl J Med; 2018 Nov; 379(21):2027-2039. PubMed ID: 30280657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Second- and third-generation ALK inhibitors for non-small cell lung cancer.
    Wu J; Savooji J; Liu D
    J Hematol Oncol; 2016 Mar; 9():19. PubMed ID: 26951079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
    Yoshimura Y; Kurasawa M; Yorozu K; Puig O; Bordogna W; Harada N
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):623-8. PubMed ID: 26849637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alectinib for ALK-positive non-small-cell lung cancer.
    Rossi A
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1005-13. PubMed ID: 27232673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brigatinib Effective in ALK+ NSCLC.
    Cancer Discov; 2017 Jan; 7(1):4-5. PubMed ID: 27899405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brigatinib for
    Ali R; Arshad J; Palacio S; Mudad R
    Drug Des Devel Ther; 2019; 13():569-580. PubMed ID: 30804663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
    Karachaliou N; Santarpia M; Gonzalez Cao M; Teixido C; Sosa AE; Berenguer J; Rodriguez Capote A; Altavilla G; Rosell R
    Expert Opin Investig Drugs; 2017 Jun; 26(6):713-722. PubMed ID: 28463570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.
    Huang D; Kim DW; Kotsakis A; Deng S; Lira P; Ho SN; Lee NV; Vizcarra P; Cao JQ; Christensen JG; Kim TM; Sun JM; Ahn JS; Ahn MJ; Park K; Mao M
    Genomics; 2013 Sep; 102(3):157-62. PubMed ID: 23434628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brigatinib versus crizotinib for ALK-positive NSCLC.
    Stirrups R
    Lancet Oncol; 2018 Nov; 19(11):e585. PubMed ID: 30293790
    [No Abstract]   [Full Text] [Related]  

  • 35. Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario.
    Addeo A; Tabbò F; Robinson T; Buffoni L; Novello S
    Crit Rev Oncol Hematol; 2018 Feb; 122():150-156. PubMed ID: 29458783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).
    Popat S; Liu G; Lu S; Song G; Ma X; Yang JC
    Future Oncol; 2021 Nov; 17(32):4237-4247. PubMed ID: 34423676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.
    Amanam I; Gupta R; Mambetsariev I; Salgia R
    Future Oncol; 2018 Aug; 14(19):1897-1908. PubMed ID: 29451020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.
    Lin JJ; Zhu VW; Schoenfeld AJ; Yeap BY; Saxena A; Ferris LA; Dagogo-Jack I; Farago AF; Taber A; Traynor A; Menon S; Gainor JF; Lennerz JK; Plodkowski AJ; Digumarthy SR; Ou SI; Shaw AT; Riely GJ
    J Thorac Oncol; 2018 Oct; 13(10):1530-1538. PubMed ID: 29935304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular inhibitory mechanism study on the potent inhibitor brigatinib against four crizotinib-resistant ALK mutations.
    Tu J; Song LT; Liu RR; Zhai HL; Wang J; Zhang XY
    J Cell Biochem; 2019 Jan; 120(1):562-574. PubMed ID: 30191596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer.
    Han R; Lu CH; Hu C; Dou YY; Kang J; Lin CY; Wu D; Jiang WL; Yin GQ; He Y
    Acta Pharmacol Sin; 2024 Jun; 45(6):1264-1275. PubMed ID: 38438582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.